Although the American Society of Clinical Oncology meeting in Orlando, Fla., which wrapped up last week, spewed much data and generated plenty of talk, the news wasn't all good for biotechnology firms, nor was it all bad. In a down market, however, the word "mixed" doesn't carry quite the cautious optimism it once did at least not for those with cash on the line. (BioWorld Financial Watch)